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Strengths and limitations of this study
 Ź In- depth interviews generated detailed data about 
complex experiences before diagnosis.
 Ź The views of patients and relatives are captured, 
within contemporary healthcare systems.
 Ź Maximum variation sampling ensured that indings 
are largely transferable to similar settings.
 Ź Patients were largely interviewed within a year of 
diagnosis and some used diaries to promote recall.
 Ź As the sample was derived from individuals return-
ing a questionnaire about their symptoms and help 
seeking, the views of people unable to do this are 
not captured.
AbStrACt
Objectives To explore alignment of experiences before 
lymphoma and myeloma diagnosis with the appraisal, help 
seeking and diagnostic intervals in the Model of Pathways 
to Treatment (MPT).
Design A qualitative study using in- depth semistructured 
interviews with patients and relatives. Interviews were 
transcribed verbatim, anonymised and analysed using 
qualitative description.
Setting A UK population- based haematological 
malignancy patient cohort.
Participants Fifty- ive patients (35 lymphoma, 20 
myeloma: diagnosed 2014–2016) and 28 relatives 
participated, within around a year of the patient’s 
diagnosis. Patients were selected from those in the cohort 
who had returned a questionnaire about their symptoms 
and help seeking, and consented to contact for further 
research. Sampling was purposive, to achieve maximum 
variation in age, sex and time to diagnosis.
results Participants described time from symptom 
onset to diagnosis as ranging from several weeks to 
years. Pathways largely aligned with MPT components 
and help seeking could lead to the rapid investigations 
and identiication of abnormalities. However, symptoms 
could be vague and/or inadvertently interpreted as other 
conditions, which if perpetuated, could cause diagnostic 
delay. The latter was associated with chaotic pathways, 
with activities rarely occurring only once or in a linear 
sequence. Rather, intermittent or ongoing processes 
were described, moving forward and backwards through 
intervals. This is ‘unpacked’ within ive themes: (1) 
appraisal and reappraisal; (2) patient- initiated self- 
management/treatment; (3) initial help seeking; (4) re- 
presentation; and (5) patient- initiated actions, decisions 
and emotions during re- presentation. Within these themes, 
various healthcare professionals were consulted, often 
many times, as symptoms persisted/progressed. Input 
from family/friends was described as substantial, as was 
the extent to which information seeking occurred.
Conclusion Lymphoma and myeloma pathways align 
with the MPT, but do not fully capture the repetition and 
complexity described by participants. Time to diagnosis 
was often prolonged, despite the best efforts of patients, 
relatives and healthcare professionals. The impact of 
National Health Service England’s Multi- diagnostic 
Disciplinary Centres on time to haematological cancer 
diagnosis remains to be seen.
IntrODuCtIOn
Early diagnosis of symptomatic cancer can 
lead to improved quality of life and survival,1 2 
and has been a long- term UK policy priority, 
promoted via general practitioner (GP) 
referral guidelines and waiting- time targets.3–5 
The impact of such measures has been vari-
able, however, with substantial reductions in 
time to diagnosis seen for some cancers, but 
limited benefits for others; and some actu-
ally seeing increases.6 Further targets and 
initiatives introduced in the recent National 
Health Service (NHS) Long Term Plan,7 as 
well as a broader range of potential pathways 
to diagnosis,8 9 confirm this as an area that 
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Figure 1 Model of Pathways to Treatment (MPT).27 HCP, healthcare professional.
continues to be clinically relevant, with early diagnosis 
still considered key to improving UK cancer survival.
Arising in blood and lymph forming tissues, haema-
tological malignancies (leukaemia, lymphoma and 
myeloma) are collectively the fourth most common cancer 
among men (after prostate, lung and bowel) and women 
(after breast, lung and bowel) in economically devel-
oped regions of the world.10–13 With diverse pathways and 
treatments, WHO currently recognises over 100 hetero-
geneous haematological malignancy subtypes, which 
display a range of behaviours and outcomes.14 Myeloma, 
for example, generally presents in the bones and often 
requires intermittent treatment throughout a remitting–
relapsing pathway, that is more typical of chronic disease 
than cancer. Non- Hodgkin lymphoma and Hodgkin 
lymphoma each have further subtypes, arise in various 
nodal/extranodal site(s) and may be indolent or aggres-
sive. Myeloma and indolent lymphomas (eg, follicular 
lymphoma) are considered incurable at diagnosis, but 
can often be controlled for long periods of time. Aggres-
sive lymphomas (eg, diffuse large B- cell lymphomas) are 
potentially curable with chemotherapy, but many patients 
still die from these diseases.
Patterns of disease onset and time to diagnosis of 
lymphoma and myeloma are varied. For example, 
patients may be asymptomatic and diagnosed inciden-
tally or they may have multiple and/or severe symptoms, 
that can be diverse and similar to other self- limiting 
conditions (eg, fatigue, bone pain, swollen glands) to 
which they are often initially attributed or ‘normalised’; 
symptoms may also be vague and non- specific in onset or 
intermittent.15–17 Importantly, time to diagnosis can be 
prolonged and associated with multiple GP consultations 
before hospital referral,18–23 myeloma being one of very 
few cancers that has seen increases in time to diagnosis 
in recent years, despite policy initiatives.6 Emergency 
presentation is comparatively common in these cancers, 
a route linked to advanced disease, more complications 
and poorer survival than other pathways.24–26 Conversely, 
fewer 2- week wait referrals are made to secondary care 
and more routine GP referrals than for other malignan-
cies, suggesting cancer is not suspected at the time of 
hospital referral.
In the UK, a contemporary schematic template (known 
as the Model of Pathways to Treatment: MPT, figure 1)27 
is recommended for mapping and examining pathways to 
cancer diagnosis, along with a checklist to ensure consis-
tent definitions, terminology, methods, data collection 
and reporting between studies.28 The MPT comprises 
a series of intervals beginning with appraisal (patient 
appraisal of symptoms and self- management); followed 
by help seeking (decision to consult a healthcare profes-
sional (HCP), and make and attend an appointment); 
the diagnostic interval (HCP appraisal, investigation and 
referral); and the pretreatment interval (diagnosis to the 
start of treatment). Each interval is impacted by contrib-
uting factors, including patient actions, healthcare 
systems and disease characteristics. The MPT authors 
acknowledge that the intervals they describe may require 
‘unpacking’ by cancer type.27 The overarching aim of the 
current paper is to address this by unpacking the MPT, 
based on the experiences described by patients with 
lymphoma and myeloma and their relatives, in the time 
leading to diagnosis.
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Table 1 Overview of patient characteristics (n=55) and involvement of relatives by diagnostic group (n=28)
Diagnosis
Patients 
(relatives*)
Total 
females
Total 
males
Median age
years (range)
Duration of intervals (months/range)
Appraisal/help 
seeking† Diagnostic‡ Total§
Non- Hodgkin lymphoma
  Diffuse large B- cell 12 (7) 5 7 64 (48–81) 0.5–13 1–15 2–17
  Follicular lymphoma 9 (3) 4 5 63 (39–84) 0.5–12 1.5–12 2–15
  Marginal zone 6 (1) 4 2 62 (57–76) 0.5–11 3–25 3.5–25.5
  Mantle cell 3 (3) 2 1 71 (70–75) 1–6 2–10 2.5–10.5
Hodgkin lymphoma 5 (2) 2 3 36 (23–56) 0.5–12 1–12 3.5–13
Myeloma 20 (12) 14 6 68 (43–78) 0.5–7 0.5–17 2–18
Total 55 (28) 31 24 64 (23–84) 0.5–13 0.5–25 2–25.5
*Spouses, partners, children.
†Initial symptom/health change to irst help seeking (from information estimated by patients completing the routine self- reported 
Haematological Malignancy Research Network (HMRN) questionnaire).
‡First help seeking to diagnosis (start point also estimated from the self- reported HMRN questionnaire).
§Initial symptom/health change to diagnosis.
MethODS
Given the difficulties described above in achieving 
lymphoma and myeloma diagnosis, a mixed methods 
study was set up to explore the experiences of patients 
(and relatives) before diagnosis, which has, to date, 
resulted in several publications using data from medical 
records and qualitative interviews.16 17 25 The current paper 
is based on the qualitative study phase, the methods of 
which are outlined below in accordance with the Consol-
idated criteria for Reporting Qualitative research.29 Qual-
itative data are known to be well suited to investigating 
how people make sense of their situation, and how and 
why they make particular decisions.30 In this study, our 
theoretical approach adhered to the principles of quali-
tative description,31 32 an applied method facilitating the 
production of concrete, low inference descriptions with 
practical relevance. The MPT27 was used as a framework 
from which to examine activities within the appraisal, 
help seeking and diagnostic intervals, as this is where the 
most significant delays are considered to occur.17
The qualitative study examining diagnostic path-
ways was based within the UK’s Haematological Malig-
nancy Research Network (HMRN: www. hmrn. org), 
detailed methods of which have been published else-
where.33 34 Briefly, HMRN is a specialist population- based 
cohort which was initiated in 2004. It tracks entire treat-
ment pathways and collects data on all patients newly 
diagnosed with haematological malignancies across 14 
hospitals (catchment population ~4 million) in the North 
of England (Yorkshire and Humberside). In addition 
to clinical data collection, HMRN patients are routinely 
asked to complete a questionnaire about their symptoms 
and help seeking.
Potential interviewees for the qualitative study were 
derived from patients completing the routine question-
naire in the HMRN area, who were aged ≥18 years, and 
within around 12 months of diagnosis. Sampling was 
purposive and designed to achieve maximum variation in 
age, sex and time to diagnosis. Ninety- two people were 
posted study material and invited to contact the research 
team if they wanted to participate; they were also invited 
to ask a relative/carer to contribute to the interview if they 
wished. Fifty- five patients (diagnosed 2014–2016; 20 with 
myeloma; 35 with lymphoma) and 28 relatives were inter-
viewed, with data collection continuing until saturation. 
An overview of patient characteristics and the duration 
of intervals can be found in table 1, with further informa-
tion provided in the .online supplementary table 1.
Interviews (conducted November 2015–May 2016 by 
RH and DH, both of whom were previously unknown 
to participants) were semistructured and guided by a 
schedule, developed from existing literature, as well as 
clinical advice from within the study team (box 1). With 
written consent, patients were asked to describe their 
pathways from first symptom(s) or health change(s) to 
diagnosis. Most interviews were carried out face to face 
in the patients home, although several were conducted 
in hospital or university settings, and a minority occurred 
by telephone. Interviews lasted around 45 min and were 
audio recorded, transcribed, anonymised and checked, 
with field notes used to confirm accuracy and support 
data analysis.
Analysis was iterative, running alongside and informing 
data collection (RH, DH). After review and familiarisa-
tion with transcripts, narrative summaries were produced 
from the data and pathways were mapped out visually and 
shared with the research team (ER, AS). Several rounds 
of coding were undertaken, focusing on different aspects 
of the data, including activities and events occurring 
within intervals defined in the MPT. Constant compar-
ison (codes with codes, codes with data, codes with 
theory) and memoing35 supported refinement of codes 
and identification of patterns and relationships. Codes 
and emerging themes were discussed by the team and 
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box 1 Overview of interview schedule
Interviewees were asked to describe:
1. Initial and subsequent symptoms and health changes
2. Interpretation of symptoms and health changes
3. Response to symptoms between onset and diagnosis: actions; ac-
tivities; events
4. Help- seeking episode(s) and factors inluencing this
5. Where, when and with whom help seeking occurred
6. Management by healthcare professionals (primary/secondary care)
Figure 2 Summary of key themes and components. 
A&E, Accident and Emergency department; GP, general 
practitioner; HCP, Healthcare Professional; NHS, National 
Health Service.
refined until consensus was reached. Input from relatives 
was analysed alongside that of the patient, using the same 
methods.
Patient and public involvement (PPI)
PPI is integral within HMRN, and takes place via a dedi-
cated partnership, overseen by a lay committee. Patients 
from the partnership were involved in identifying the 
research questions underpinning the study during several 
focus group meetings, where they highlighted the diffi-
culties they had experienced getting diagnosed; they were 
also involved in study design via our funding application. 
Furthermore, patients routinely assist in the dissemina-
tion of all HMRN findings, which also occurs via our lay 
website: www. yhhn. org.
FInDIngS
Participants described time from symptom onset to diag-
nosis as ranging from several weeks to numerous years. 
Within this disparate time frame, pathways largely aligned 
with the MPT, although experiences were more chaotic 
and did not always fit this model’s distinct intervals or 
linear trajectory. This is ‘unpacked’ within five themes: 
(1) appraisal and reappraisal; (2) patient- initiated self- 
management/treatment; (3) initial help seeking; (4) 
re- presentation; and (5) patient- initiated actions, deci-
sions and emotions during re- presentation. Each theme 
is described using illustrative verbatim quotes and 
summarised in figure 2.
Appraisal and reappraisal
Patient appraisal of symptoms and health changes was 
described as ongoing by participants, with observa-
tion and monitoring occurring periodically or contin-
uously from first symptom to diagnosis. When ‘normal’ 
health was not regained, appraisal was said to become 
more deliberate and rigorous. It involved, for example, 
checking and comparing affected and non- affected sites: 
‘My mind was going, “If you can feel (a lump)…both sides, 
then it’s normal. If you can feel it on one side, then that’s 
something to worry about”. So I tried, I felt the other 
side, and again…’ [Lymphoma patient 06: L06]. This was 
said to take place repeatedly over time: ‘I couldn’t decide 
whether my skin was a different colour…I’d look at it and 
think, “It looks strange”, and then I’d look again, and it 
didn’t’ [L03].
Interviewees described reappraising persistent, 
progressive or new symptoms, which could be perceived 
to be related, or unrelated, to the initial problem. Unre-
mitting symptoms sometimes led to more precise and 
formal appraisal, including documentation of health 
changes, pain, medication and weight: ‘I kept a note, like 
week- by- week almost’…[L25]. A key element of appraisal 
involved patients and relatives considering numerous 
explanations for their symptoms over time. This included 
‘normalisation’ of symptoms by attributing these to life- 
course issues (eg, age or menopause related) or events/
activities (eg, decorating), or self- limiting conditions: 
‘Could I have ME?’ [L05]; ‘Maybe it was an ulcer’ [L26]; 
‘I was just thinking, “actually, is this becoming a mental 
health issue? Is it (the) first signs of dementia?”’ [Relative 
of myeloma patient 20: M20].
Interviewees described information seeking from 
various sources during appraisal/reappraisal, particu-
larly for ongoing symptoms; an issue not wholly acknowl-
edged in the MPT. One myeloma patient consulted 
relatives about their family history (osteoporosis) as a 
potential explanation for symptoms. Others described 
questioning medically experienced friends, colleagues 
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or acquaintances: ‘There’s a doctor…lives further down 
the lane…I said [to him] “I don’t really like asking 
but…”’ [L03]. Many explored symptoms via the internet: 
‘I’d looked at all sorts of problems I thought (patient) 
might be having with bones”’ [Relative, M20]. Internet 
searching was more effective when symptoms were typical 
of myeloma or lymphoma: ‘I think I put in something 
like “itchy skin, night sweats, lump in neck”; Hodgkin’s 
lymphoma came up, through a few different clicks’ 
[L14]. This could lead to rapid help seeking/re- presen-
tation: ‘had I not seen (information), I’m not convinced 
I would have said anything to the doctor, but because I’d 
seen it and I thought, “Crying out loud…”, I was like, 
“We’ve got to do something…someone needs to put all 
these pieces of the puzzle together”’ [Relative, L14]. It 
could also lead to emergency presentation: ‘the more I 
read (about lump), the more I was scared, and I just went 
to A&E…”’ [L23]; or denial: ‘Well, when I started reading 
about cancer I just switched it off, because I thought, “No, 
no, that’s not right”’ [L05].
Considerable involvement of relatives, friends and 
colleagues in appraisal/reappraisal was described, though 
not wholly depicted in the MPT: 'I just looked at his 
tummy and I thought, “that’s an odd shape, that”, and it 
just flashed through my mind and I thought “That could 
be a tumour”’ [Relative: L20]. Some relatives said they 
adapted their own behaviour to accord with the patient, 
often over long time periods: ‘patient’s) height loss, was 
gradual, at first, so, I noticed…I stopped buying shoes 
with heels, because I was getting to be, you know, too tall 
(for him) when I was wearing shoes with heels…That had 
probably been going on…maybe a couple of years’ [Rela-
tive: M18]; or they began to discuss the patient’s symp-
toms and health changes between themselves: ‘We knew 
there was something wrong…my daughter actually said, 
“You know, dad’s not right at all, is he?”’ [Relative: M02].
Patient initiated self-management/treatment
Self- management was not solely associated with the 
appraisal interval as portrayed in the MPT, but was 
described as occurring throughout the pathway, particu-
larly if patients or HCPs had normalised initial symptoms 
to self- limiting or life- course issues (eg, age, menopause): 
‘we’re the kind of people who go to the doctor as a last 
resort, and we’d tried the obvious things ourselves, you 
know (lists remedies for indigestion), anything you think 
might ease it. But it didn’t…’ [Relative: L20].
Some patients said they used distraction techniques for 
relief, often long- term: ‘I wake up because my tummy’s 
hurting, and then I get up and start the day, and then I 
try and fill my day with things, so that I don’t think about 
it…and, that was how it went and, we’re probably talking 
a couple of years of that…just putting up with these 
different things’ [L26]. Others reduced or stopped activ-
ities viewed to cause/aggravate problems: ‘You’d stopped 
driving for about two months (before diagnosis), because 
you were in…pain’ [Relative: M03]; [Interviewer: ‘You 
gave up work 18 months ago…?’] ‘Yeah…it were getting 
a little bit difficult for me, and I didn’t want to embarrass 
myself’ [L16].
People described using aids over long time periods: ‘I 
used to go to work with that belt (meant for weight- lifting), 
you know, on my back’ [M15]. Others used sticks, wheel-
chairs or riser chairs to remain mobile. Lifestyle changes 
were made: ‘I’ve had grumbling problems… probably at 
least two years…the kind…you treat yourself, with indi-
gestion medicine, drinking water, trying to eat well, going 
for exercise, all those things that you think “This’ll sort 
me out. I’m just getting a bit older and I need to look 
after myself” [L26]. Some took supplements ‘we were 
having Complan drinks with whole milk…protein drinks, 
powders, anything to get something into his system…the 
weight back’ [Relative: L20]; or self- medicated with anal-
gesics, anti- inflammatories, antihistamines and gargles.
Long- term strategies were reported to manage debili-
tating tiredness, including napping or sleeping more: ‘I 
were feeling tired all the time…I used to eat my sand-
wiches before my lunch…as I went round, and then as I 
stopped the van, I used to turn the ignition off, and lay on 
the seat, and go to sleep’ [L16]; ‘I tended to sleep a lot. 
I’d come home for lunch at 12 o’clock…fall asleep in the 
chair… almost every day…’ [M12]. And then you’d come 
home and fall asleep, and you’d wake up and have tea, 
then fall asleep again, and then wake up for a couple of 
hours watching telly, and then go to bed’ [Relative: M12].
Some people said they chose to pay for specific treat-
ments, with mixed results: ‘(physiotherapy) made matters 
worse’ [M18]; ‘eventually, he were in that much pain, he 
couldn’t go… (to physiotherapy)’ [Relative: M15]; ‘I went 
to an osteopath…which did help’ [M12]. An ‘herbalist’ 
and an ‘allergist’ were also consulted and one person 
considered ‘colonic irrigation’.
Initial help seeking
Concurring with the MPT, all patients described help 
seeking for symptoms and attended their GP . The deci-
sion to seek help and the timing of this was often said 
to be influenced by relatives, friends or colleagues, who 
could encourage help seeking: ‘My mum and friends 
(were) saying, “You…really ought to go to the doctors”’ 
[M05]; or indeed discourage it: ‘I had these lumps on 
my neck and I, I didn’t take any notice of them…I said to 
a friend and she said…“Oh it’s nothing, everybody gets 
lumps”’ [L15].
A minority said initial help seeking led to the rapid 
identification of abnormality/suspected cancer, which 
was quickly investigated and diagnosed: ‘The doctor…
was lovely and she examined (patient)…and said “I can 
feel something, in there, and she booked him in…for a 
CT scan…endoscopy, yeah, and a blood test…on the scan 
they saw, there was a mass’ [Relative: L20]; ‘(GP) did a 
very thorough check…he’s always been very thorough…
physical and, yeah, mental if you like…I’ve always found 
him absolutely superb. (He) listens not just to what you 
say, but what you don’t say and, and sort of, reads the 
signals; [L01]; (GP) decided it was something serious, 
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and then you were sent for a scan…you had a biopsy, and 
it all happened very quickly’ [Relative: L01].
Initial help seeking could include requests for broad 
health checks: ‘I just felt, okay I’ll go to the doctor’s and…
(say), “Well, I want an MOT…I seem a bit tired”…and it 
was a locum, and I explained my symptoms, and he sort 
of said, “Well, they seem a bit of an odd set of symptoms, 
so we’ll give you…full blood tests”, and thank goodness 
he did’ [M05]; ‘I did sort of ask for like a ‘well woman’ 
check, because I didn’t in my mind feel like I was right’ 
[L17]. General interventions were also sought: ‘I was just 
really feeling fed up, because I was so tired…I went for a 
tonic, I said, “Can you give me just something to pick me 
up?”’ [L34]. Alternatively, other conditions were initially 
suspected, particularly if these conditions had symptoms 
that were also associated with myeloma or lymphoma: ‘I 
noticed a swelling at the top of my groin…(GP) said “that 
feels like a, a hernia to me…I’ll sort you out an appoint-
ment to get you referred”’ [L06].
re-presentation
As initial help seeking only rarely led to diagnosis, re- pre-
sentation was extremely common. This was said to occur 
quickly with increasingly alarming symptoms: ‘(I) went 
to the bank, and wet myself… and I thought, “Oh my 
God… what’s going on here?” And I went (back) to the 
GP’ [L09]; ‘the sickness…he started bringing his evening 
meal up, and unable to sleep at night, the pressure on his 
tummy…he’d be walking the floor, you know, just gener-
ally, obviously something very wrong [L20]’. It could be 
delayed if the patient was told resolution may take time: 
I saw two (GPs)… [Interviewer: Who said?] ‘Give it time’ 
[M13]; or if symptoms were intermittent: ‘he’d be ok for 
a while, and then, you know, maybe a few nights he’d be 
sick’ [Relative: L20]; ‘I carried on working, as you do…I 
didn’t feel too bad really, some of the time’ [L20].
Alternatively, repeat GP consultations could be delayed, 
particularly if initial/differential diagnoses were perpetu-
ated: ‘I noticed, like, a little pea- sized lump in my leg…
my right calf…I thought… “Probably me varicose veins”. I 
didn’t rush, I went to see the doctor, regarding something 
else, and I just happened to mention to him about it… 
he had a feel of it, and he says “right, we’ll send you off 
to have and ultrasound”, you know, get it checked out. 
I asked (radiographer)…“Is it a varicose vein?” She says 
“yes”. ‘I got on with my life, I just carried on. I thought 
well fair enough, you know, its varicose veins…I never 
bothered when I started getting other lumps in my leg, I 
thought, “well it’s all just part of it”. (The following year) 
this lump was steadily growing…I started getting other 
lumps…the lumps joined together…starting to turn red 
and poke out of my skin…It just sort of exploded sort of 
thing, you know, it was frightening how fast it was grow-
ing…I went to see the doctor again’ [L31].
Re- presentation often occurred on multiple occasions: 
‘I went back probably about three times between February 
and August… [M13]; ‘all that time, just going backwards 
and forwards to the doctors’ [Relative: L24]. Sometimes 
this was associated with ongoing normal investigations: ‘I 
just felt so tired. I’d just no energy, you know, and the 
daft part is, I think I’d three lots of blood tests done as 
well, to try and find out, you know, and yet none of ‘em 
showed anything to do with the lymphoma’ [L31]; ‘The 
blood test revealed nothing, did it, and neither did the 
camera in the stomach’ [L20]. Where abnormal blood 
tests were noted, rapid hospital referral was described: 
‘I’d had about four or five different blood tests, and it 
were all coming back negative’ [M15]…‘til these blood 
tests did come back abnormal, all of a sudden, so that’s 
when they sent him up to haematology [Relative: M15]; 
‘(GP) immediately, more or less said, I’m sending you 
into hospital. You’re anaemic’ [L24].
Repeat consultations sometimes occurred at the request 
of HCPs: ‘(GP) said to me if there are ever any changes 
with the lumps to inform him’ [M12]. This was sometimes 
associated with HCPs expressing frustration about their 
inability to explain symptoms: ‘(GP) said: “come back in 
four weeks…I’m getting me books out…I don’t under-
stand what the symptoms are pointing me to” [L24, para-
phrasing GP]. Interestingly, this patient’s main concern 
(‘night urination…combined with the loss of weight, that 
was what really got me, erm, worried’), remained unre-
solved after successful treatment, and at this point was 
considered unrelated, with urology review awaited.
Re- presentation also occurred due to a growing convic-
tion something was really wrong: ‘Normally I’m not some-
body who goes to (the) doctors…it was just a feeling that 
something definitely wasn’t right. Despite getting the first 
opinion’ [L01]; My mobility was shocking by then…I was 
having great difficulty in doing anything, literally and I 
knew then that there was something…’ [M03]; ‘I weren’t 
going to take “no” for an answer… because I knew there 
was something’ [L34]. Doubt about an earlier expla-
nation was often key: ‘I was convinced there was some-
thing wrong with me, other than osteoporosis, because I 
thought “I shouldn’t feel, this unwell, with osteoporosis.”’ 
[M14].
HCPs directed a number of patients towards emer-
gency (re)presentation, either via A&E or a direct ward 
admission, often for worsening symptoms and to gain 
rapid access to healthcare. ‘I saw the nurse, and she said, 
“Look, you know, go to A&E and let them have a look 
at it, so that’s what we did’ [L31]. Symptom complexity 
could result in consultation with multiple specialists even 
via this route, with the same patient being assessed by the 
A&E team, then a physiotherapist, vascular surgeon and 
plastic surgeon, before being told “it’s a tumour” [L31].
Patient-initiated actions, decisions and emotions during re-
presentation
Some interviewees described requesting more specific 
input from their HCP at re- presentation, including 
direct appraisal: ‘you need to see my neck again’ [L14]; 
‘have a look while I’m standing up’ [L34]; ‘I said to 
(GP)…“Can you actually measure me?” which she did…
she indicated… that I’d lost about two inches’ [M14]; 
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and particular investigations: ‘I said, “Look, there’s some-
thing wrong here. I need an X- ray”’ [M13]; ‘I said “I’m 
not picking up” and she agreed (to blood tests)’ [L05].
Evidence (eg, diaries) was often produced by patients 
at re- presentation to demonstrate the extent and severity 
of symptoms: I thought, “(GP’s) probably thinking I’m 
just a hypochondriac”. But when I got the evidence of 
the weight that I was losing, I didn’t feel that…(GP) 
could turn a blind eye to that.’ [L25]. New informa-
tion from re- appraisal (symptoms, mismatch between 
symptoms and preliminary diagnoses, and test results) 
or internet searching was also said to be passed on to 
HCPs: ‘I said, “I think I’ve got lymphoma…I seem to have 
these lumps that haven’t gone down at all…and I think 
now I’m getting, it’s either anxiety, or I’m now getting 
B- symptoms, which is night sweats…”’ [L06]. This could 
prompt action: ‘I went back to the GP and said, “Well, 
(ENT) say it’s TB or lymphoma”, and the GP said, “Well, 
I don’t think it’s lymphoma, but, if they’re saying TB, I’ll 
send you for an X- ray”’ [L07]; but not always: ‘I’d been 
in pain for a long time, and I actually said, “I think I’ve 
got cancer” and (Dr) said to me, “You don’t look like 
somebody who’s got cancer”’ [M14]; ‘(GP) said, “No, 
no, you haven’t…lymphoma, old people get lymphoma. 
You’re (under 40)…don’t even think about that”’ [L06]. 
Patients reported chasing- up information to give to HCPs 
(eg, results): ‘I rang (surgery), three times a week, every 
week, to see if they’d had a reply’ [Relative: L11].
Others blamed themselves for their delayed diagnosis, 
saying they only gave HCPs partial information about 
their symptoms: ‘maybe I wasn’t forthcoming with the 
information’ [M03]; either purposely (only reporting 
symptoms they thought the HCP would considered 
important) or inadvertently: ‘I didn’t mention my general 
apathy, because I just thought it was just apathy to be 
honest’ [M12]; ‘many’s the time I’ve come out thinking, 
“Oh damn, I didn’t mention that”’ [L24].
A few patients described feeling obliged to ‘stick with’ 
the first GP consulted: ‘he knew the situation, and I kind 
of felt like, it’d have been going behind his back to go 
and see another GP’ [L07]. Others did not: ‘The very first 
doctor I saw. I saw him twice and then I knew after that 
I wasn’t going to ask for that particular doctor’ [M14]. 
Some reported re- presenting to HCPs they knew and 
trusted, were more experience, or just different: ‘We 
would sometimes just ask for a different one, just to get 
a different opinion’ [L34]. Decisions were also made to 
consult various other specialists: ‘I’d started to suffer with 
mouth ulcers, and…I actually went to my dentist’ [L30]; 
and advice was sought at unrelated hospital appoint-
ments: ‘I went to see my Crohn’s surgeon… my normal 
check- up, and I mentioned (the lump) to him, and he’s 
the one really who pushed it forward fast…’ [L32].
Lack of progress towards diagnosis could lead patients 
and relatives to ask their HCP to refer/admit them to 
hospital, which could be refused: ‘“Oh no, she doesn’t 
need to go to hospital”’ [Relative paraphrasing HCP, 
L35]. It also resulted in distress, anxiety and frustration: 
‘‘I was getting towards my wits’ end, because I knew that 
there was something wrong, and I just felt as if (HCPs) 
weren’t taking me seriously’ [L06]. Occasionally, this 
resulted in emotional outbursts: ‘The doctor said, “Have 
some antibiotics”… and we broke down and were just 
like, “This isn’t right”. So he called the hospital and got 
(patient) into hospital’ [Relative, L14]; ‘They thought it 
was anxiety, because I’d got myself in a state, and I was 
in a tearful mess at the doctor’s, because of feeling ill 
and they’re not getting anywhere…So she just thought it 
was an anxiety issue. It was like turned from one thing to 
something else’ [L17].
Patients said their relatives often attended later GP 
appointments with them to advocate on their behalf: ‘you 
become increasingly dependent on somebody to go with 
you…for reassurance and support’ [M14]; ‘We made and 
appointment…we had to insist (patient) needed to see 
someone, and we went together, and we said, “we need 
help here”’ [L20]; ‘“I’m not waiting for this appointment”, 
I said, “because (patient) can’t wait”. I said, “I want him to 
see (haematologist), as soon as!” I said, “I know you can 
do it, because I worked in the health- service” so she said, 
“Yes, okay”. Otherwise, I honestly thought he could sit in 
the chair and just go (die). He was so ill’ [Relative: L11].
Some patients and relatives recalled emergency presen-
tation to hospital via A&E, which they initiated them-
selves: ‘I was getting so desperate…I knew something was 
wrong, and I felt that nobody was really listening to what 
I was saying. I did actually go to A&E a couple of times. 
Well, once under our own steam, and once we rang 111, 
and they said “Go to A&E”’ [M14]. Several people also 
mentioned eventually seeking private investigations and/
or hospital referral, which they considered key to diag-
nosis. Access to private healthcare was said to be rapid: 
‘it bought me time’ [L13]. Where GPs knew patients had 
private insurance, they were reported to suggest referral ‘I 
went backwards and forwards to my GP, and I’m covered 
by my husband’s private hospital thing, so (GP) suggested 
that I went to see a consultant back specialist’ [L09]. More 
commonly, patients portrayed private care as an extreme 
but necessary measure: ‘the timeframe for me was…it was 
too much, so I said “I want a private referral”’ [M12].
DISCuSSIOn
Principal indings
Pathways to lymphoma and myeloma diagnosis largely 
aligned with the MPT.27 However, further unpacking 
confirmed that trajectories were often much more 
complex and chaotic than depicted in the model, with 
activities rarely described as occurring on a single occa-
sion or in a linear sequence. Rather, intermittent or 
ongoing processes were said to occur, that could move 
patients forward through intervals (eg, appraisal to 
help seeking), but also return them to the start of the 
pathway if there was no suspicion of cancer or a serious 
illness. In this context, repeat/continuous reappraisal 
could occur, with multiple re- presentations to HCPs and 
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associated anxiety and distress for patients. Symptoms 
were normalised15 and self- management occurred across 
pathways, not only within the appraisal interval. Input 
from family and friends was substantial in all intervals, as 
was the extent to which independent information seeking 
occurred. Disease, patient and HCP factors (as presented 
in the MPT model) were found to influence each part of 
the pathway, with symptoms and events at one time- point 
(eg, GP reassurance about symptoms or a normal inves-
tigation) influencing later actions and time scales (eg, 
delayed patient re- presentation; delayed HCP referral to 
hospital). Similar experiences were reported by patients 
with myeloma and lymphoma (although more patients 
with myeloma were referred to hospital by the GP after an 
abnormal blood test); and various HCPs were consulted 
throughout the diagnostic interval.
Strengths and weaknesses
This is the only qualitative study exploring pathways to 
diagnosis of lymphoma and myeloma in the context of 
the MPT, while taking an overview that tries to capture 
the interactions between people (patients, relatives and 
HCPs) and the events/activities taking place throughout 
the pathway. Our study included people diagnosed within 
contemporary healthcare systems, and after introduc-
tion of UK referral guidelines, targets and urgent diag-
nostic routes.3–5 The sample is comparatively large (55 
patients; 28 relatives) and in- depth discussions ensured 
that findings were based on personal experiences and 
perceptions. Inclusion of relatives is a unique feature and 
a particular strength, as these individuals (spouses, part-
ners and adult children) were able to contribute their 
own views of the pathway and their involvement in events. 
Participation from relatives ranged from them taking a 
minor role (eg, reminding the patient about dates and 
events), to having significant input in describing the 
pathway and their own actions and emotions. Interviews 
were conducted within a year of diagnosis and the use of 
letters, calendars and diaries was encouraged to promote 
recall. Although generalisability is not an overarching 
aim of qualitative research, maximum sample variation 
increased the transferability36 of findings to places with 
similar healthcare systems. Experiences may, however, 
differ in countries without universal healthcare provision, 
or where secondary/private healthcare gatekeepers are 
not GPs. Although we believe data saturation was reached, 
our sample was derived from individuals returning the 
routine HMRN questionnaire about symptoms and help 
seeking, so did not capture the views of people unable 
to do this, including those dying soon after diagnosis, 
who may have had more advanced stage disease. Further-
more, it is possible that symptoms attributed to myeloma 
or lymphoma by interviewees may in fact be unrelated to 
their cancer diagnosis.
Comparison to other studies
We were unable to identify any other qualitative studies 
exploring the specific experiences of patients with 
myeloma and only two targeting lymphoma.37 38 The 
latter were both UK based, and also reported descrip-
tions from patients of challenging pathways and difficul-
ties achieving diagnosis. Other quantitative work reports 
multiple GP appointments and delay before diagnosis 
(particularly among patients with myeloma); as well as the 
need to improve time to diagnosis.18–23 Further studies 
have identified a group of cancers that are ‘harder/diffi-
cult to suspect’.18 23 Myeloma is among this group due to 
its propensity for non- specific symptoms commonly found 
in the general population (eg, back pain and fatigue).19 
Other ‘harder to suspect’ malignancies include pancre-
atic, stomach, lung, colon, brain and ovarian cancers, 
and Hodgkin lymphoma, and also typically have vague 
and intermittent symptoms, as well as complex pathways 
to diagnosis, including multiple GP consultations before 
hospital referral, more emergency presentations and 
longer time to diagnosis.18 23 39–44 Conversely, malignancies 
with specific signs and symptoms (eg, breast cancer and 
breast lumps; melanoma and skin lesions), or affecting 
organs that can easily be examined (eg, testicular or 
thyroid cancer), generally have fewer GP consultations, 
more 2- week wait referrals for suspected cancer, fewer 
routine referrals and shorter time to diagnosis.18 23 39 40 43 
Given these differences, it is likely that the latter group 
will experience the linear compartmentalisation depicted 
in the MPT, whereas the former group is predisposed to 
the chaotic pathways described in this study.
Meaning of the study and implications for practice
Our study clearly depicts the complexity of pathways to 
lymphoma and myeloma diagnosis. It clarifies the difficul-
ties experienced in trying to identify the cause of what are 
often non- specific symptoms (intermittent, vague, slowly 
progressive, common in other illnesses). This difficulty 
could occur despite the best efforts of patients and rela-
tives (eg, re- presenting to GPs for reassessment), as well as 
actions taken by GPs themselves, such as requesting inves-
tigations (eg, blood tests and imaging, and colonoscopies/
endoscopies due to anaemia), which were often normal. 
Our findings highlight some of the reasons for delays in 
help seeking, re- presentation and diagnosis,18–22 as well 
as potential explanations for the lack of urgent hospital 
referrals for suspected cancer and the high proportion of 
emergency presentations.17 24–26 Our results also explain 
why interventions such as education campaigns targeting 
the (very broad) symptoms of these diseases would prob-
ably lack impact. Interestingly, some patients reported 
symptoms that were present before and after diagnosis 
(eg, nocturia: L24). While such symptoms were consid-
ered significant at the time, persistence after successful 
chemotherapy is likely to indicate that the issue was unre-
lated to their lymphoma, thus highlighting the difficulty 
of distinguishing malignant from benign disease. Moving 
forward, and in the absence of clear symptom signa-
tures and blood tests45–47 (although certain tests can rule 
myeloma in or out48), it is important that the complexity 
experienced by patients with myeloma and lymphoma, as 
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well as other ‘harder to suspect’ cancers, is acknowledged 
within strategies to reduce time to diagnosis, including 
those set out in the NHS Long Term Plan.7 Importantly, 
this document introduced Rapid Diagnostic Centres 
(RDCs) that provide GPs with an alternative fast access 
pathway to secondary care for patients with symptoms 
that are worrying, but non- specific, so do not suggest 
referral to a specific clinical discipline. This could repre-
sent a significant change in the context of myeloma and 
lymphoma, as well as other ‘harder to suspect’ cancers, 
particularly if used in conjunction with rigorous safety 
netting in primary care,4 49 of which some evidence was 
found in the current study. For members of the public, 
individual recognition of their own ‘normal’ is key, as well 
as having the confidence to pursue help seeking for unex-
plained symptoms.
unanswered questions and future research
Primary care HCPs have significant input into the care of 
patients later diagnosed with cancer, including those with 
emergency presentation.50 To our knowledge, there have 
been no qualitative studies exploring GP experiences of 
managing patients with lymphoma or myeloma. Nor is 
there any work linking primary and secondary healthcare 
data, although such studies would clarify the occurrence 
and timing of events between symptom onset and diag-
nosis and promote understanding of these complex path-
ways. Exploring the impact of RDCs on time to diagnosis 
and disease stage at diagnosis will provide insights into 
the efficacy of this new pathway for patients with myeloma 
and lymphoma.
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